Opendata, web and dolomites

FasNaGel

NOVEL THERAPEUTIC NANOHYDROGEL FOR ACUTE AND CHRONIC PAIN TREATMENT TARGETED TO THE NERVES FASCIA

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 FasNaGel project word cloud

Explore the words cloud of the FasNaGel project. It provides you a very rough idea of what is the project "FasNaGel" about.

hyaluronic    first    consists    unemployment    negative    direct    productivity    80    prematurely    mill    porous    professional    2014    drug    anti    marketing    271    effectiveness    injectable    medicines    pain    perform    people    chronification    team    billion    fast    imed    started    30    commercialization    worldwide    149    size    carrier    biocompatible    fasnagel    reduce    plane    staff    medical    post    policies    acute    track    recovery    provides    works    quality    60    containing    enormous    biodegradable    market    disability    few    absences    total    thorough    chronic    prevent    treatment    suffers    acid    operative    patients    start    greatest    steroidal    sickness    feasibility    coming    multiply    losses    exit    102    time    personal    med    labour    sme    inflammatory    functional    nanomedicinal    world    deducting    100    nanostructured    gdp    estimates    population    20    indirect    hydrogel    wrongly    depression    healthcare    validation    euros    disorders    days    made    properly    surgery    life    report    huge   

Project "FasNaGel" data sheet

The following table provides information about the project.

Coordinator
I+MED S.COOP. PEQUENA 

Organization address
address: CALLE ALBERT EINSTEIN 15
city: VITORIA-GASTEIZ
postcode: 1510
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website https://imasmed.com/portfolio-items/programas-investigacion/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-06-01   to  2018-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    I+MED S.COOP. PEQUENA ES (VITORIA-GASTEIZ) coordinator 50˙000.00

Map

 Project objective

Worldwide chronic pain conditions are by far the greatest cause of disability. It has an enormous negative impact on quality of life and on personal and professional plane. Chronic pain is an important cause of depression, more sickness absences at work, productivity losses, unemployment, etc.). Chronic pain is one of the major reasons (30%) why people exit the labour market prematurely. 20% of current population in Europe suffers from chronic pain (102 mill.) and up to 50 % of that pain comes from wrongly treated acute post-operative pain. The total direct and indirect healthcare costs for chronic pain disorders in Member States have an EU average of 2.4 % of GDP and a cost of 271 billion euros per year. When acute pain is not properly treated in the first few days, it can become chronic. About 40-60% of patients report pain chronification after surgery. Current medicines do not prevent chronic pain from the start and have side effects. “Fast track” approaches have started to take the lead in pain management policies. Based on these approaches I Med´s team works since 2014 in the development of FasNaGel, a new nanomedicinal product, unique in the world. It consists of a biocompatible and biodegradable injectable carrier, made of porous nanostructured hyaluronic acid hydrogel containing a non-steroidal anti-inflammatory drug that i) efficiently, provides a 100% of functional recovery after surgery in one third of the time, ii) is easy-to-use by medical staff, and the most important iii) increases by 80% the treatment effectiveness. FasNaGel will reduce the overall treatment costs in Europe, deducting indirect costs coming from acute pain up to €149 billion. The objective of this proposal is to be able to perform a thorough feasibility study for the validation of the production and commercialization of this novel product. FasNaGel marketing will have a huge of a SME such as iMed, who estimates to multiply the team size by 8 in 7 years.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FASNAGEL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FASNAGEL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More  

PAROST (2019)

Disruptive technology for the identification, quantification and prediction of the evolution of damages in civil engineering structures that increases safety while reducing maintenance costs.

Read More